That is the title and theme of my latest Bloomberg column, here is one excerpt:
And who should get the vaccine first? The elderly are more vulnerable, but the young are more likely to spread Covid-19. Some recent results suggest it would be better to vaccinate the young first, but that is less politically likely. Again, it is easy to see potential conflicts over this question, cutting across traditional party lines.
An even more complex problem would arise if one good vaccine is available but other, possibly better, vaccines are imminent. Does everyone get the “good enough” vaccine, disrupting the ability to conduct clinical trials to see if the other vaccines are better? How much patience do Americans have, really?
Americans would probably resent having to wait. But if they end up choosing a lesser quality vaccine, over the long run they might be unhappier yet. It is not clear the U.S. public health bureaucracy is up to the task of approving one vaccine and restructuring the other trials (possibly by paying participants more to stay in, or by shifting to other countries for data) so they can continue.
Be prepared for a mess, with almost everybody unhappy.